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To determine whether the prevalence of resistance to commonly used oral antimicrobial agents varied over
time, we compared the in vitro susceptibilities of 217 strains of Haemophilus influenzae recovered from
nasopharyngeal secretions of children in a day-care Oenter studied longitudinally between 1979 and 1987. The
overall rate of 13-lactamase production in these strains was 18%, with rates of 57% in type b isolates (n = 21)
and 14% in non-type b isolates (n = 196). The percentages of isolates for which MICs were '1.0 ,ug/ml for
amoxicillin alone, amoxicillin in combination with clavulanic acid, and cefuroxime alone were 82, 92, and 93%,
respectively. The percentage of strains for which cefaclor MICs were s1.0 ,ug/ml was only 0.5%. Isolates for
which chloramphenicol MICs were >2.0 ,ug/ml or for which trimethoprim-sulfamethoxazole MICs were
>0.5/9.5 pg/ml were uncommon: 1 and <1%, respectively. High concentrations of erythromycin alone and in
combination with sulfisoxazole were required to inhibit the majority of test strains; there was no evidence of
erythromycin-sulfisoxazole synergy. In vitro susceptibility to commonlly used oral antimicrobial agents
remained at a constant level when H. influenzae isolates collected from children in a day'catae center during
1979 through 1983 were compared with strains collected during 1984 through 1987.
Haemophilus influenzae is an important bacterial patho-
gen of the upper respiratory tract during childhood (2).
Nonencapsulated (nontypeable) strains are common causes
of conjunctivitis, otitis media, and maxillary sinusitis (9, 16,
36). Although these localized mucosal infections are rarely
life-threatening, they are associated with significant morbid-
ity; otitis media alone accounts for up to 40% of all pediatric
office visits (17, 34).
The prevalence of otitis media appears to be two to four
times higher in children attending group day-care,centers
than it is in children cared for at home or in smaller day-care
environments in homes (22, 27, 32, 35). The clinical diagno-
sis of middle ear infection in children in group day-care
centers typically results in empiric therapy with orally ad-
ministered antimicrobial agents. The frequent use of these
antimicrobial agents could contribute to the emergence of
antibiotic-resistant pathogens within pediatric populations
(13, 31). We recently reported a high rate of nasopharyngeal
carriage of antibiotic-resistant pneumococci by children in a
day-care center environment (14). In that report, we docu-
mented an increasing rate of pneumococcal resistance to
trimethoprim-sulfamethoxazole during the 5 years of its use
in that setting. Because colonizing H. influenzae strains were
exposed to the same antibiotic pressures as the previously
studied pneumococci, we were concerned that similar resis-
tance trends could be occurring in H. influenzae carried by
children in this day-care center population. The present
investigation was undertaken to determine, in a longitudinal
fashion, the prevalence of resistance to commonly used
antimicrobial agents in H. influenzae strains carried by these
attendees of a day-care center.
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MATERIALS AND METHODS
bay-care stidy population. The isolates of H. influenzae
studied were recovered from nasopharyngeal secretions of
children attel'ng the Frank Porter Graham Child Develop-
ment Center. Details of the recruiiment of these children and
of the longitudinal design of respiratory infection surveil-
lance conducted in this population have been published in
previous reports (11, 12). Briefly, a cohort of 10 to 12 infants
2 to 3 months of age was admitted to the day-care program
each year. Children attended the center for 8 h a day, 5 days
a week, 50 weeks a year. Approximately 80% of the children
ehrolled were followed continuously in this setting from
etrly infancy to entrance into kindergarten.
Recovery of isolates. Bacterial surveillance cultures of
upper respiratory tract secretions were performed each
month. In addition, samples of upper respiratory tract secre-
tions were cultured for viruses and bacteria at the onset of
each respiratory illness. Respiratory secretions were ob-
tained by performing a saline nasal wash. Aliquots of the
wash fluid were streaked onto sheep blood and chocolate
agar which idi turn were incubated at 37°C in 5% CO2.
Isolates of H. influenzae were identified by characteristic
colony morphology, Gram stain morphology, and hemin and
NAD requirement by using X-, V-, and XV-factor paper
strips (BBL, Cockeysville, Md.) (19). In addition, all of the
isolates were examined for capsular antigens by a slide
agglutination procedure by using the Bacto H. influenzae
antisera set (Difco Laboratories, Detroit, Mich.).
The test strains used in this study were isolated during the
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years 1979 through 1987 from 86 study children between 2
months and 3 years of age. Test strains collected during the
9-year study period were stored in skim milk at -70°C.
Antimicrobial susceptibility tests were performed in 1988
and 1989 by using these stored isolates.
Selection of isolates for susceptibility testing. Chronological
records of bacterial culture results for each child enrolled in
the center were used for the test isolate selection process.
Test strains were chosen such that there was a time period of
at least 90 days between H. influenzae isolations when
multiple strains from the same child were studied.
Susceptibility testing of isolates. All isolates were tested for
1-lactamase production by using chromogenic cephalosporin
(nitrocefin) reagent (Glaxo, Greenford, England) (28). In
addition, MIC antimicrobial susceptibility testing was per
formed by using agar dilution methodology (37). For amox-
icillin (Beecham Laboratories, Bristol, Tenn.), cefaclor (Eli
Lilly & Co., Indianapolis, Ind.), cefuroxime sodium (Glaxo
Laboratories Ltd., Greenford, England), and chloramphen-
icol (Parke-Davis, Morris Plains, N.J.), serial twofold dilu-
tions ranging from 0.03 to 16 jig/ml were incorporated into
Haemophilus Test Medium (HTM) prepared as described by
Jorgensen et al. (18). Briefly, HTM consists of Mueller-
Hinton agar (Difco Laboratories) with bovine hematin (15
[ig/ml; Sigma, St. Louis, Mo.), ,B-NAD (15 ,ug/ml; Kodak,
Rochester, N.Y.), and yeast extract (5 mg/ml; Difco Labo-
ratories). Amoxicillin and clavulanic acid were tested at a 2:1
ratio of amoxicillin to potassium clavulanate (Beecham
Laboratories). Serial twofold dilutions of trimethoprim
(range, 0.03 to 8 jig/ml; Burroughs-Wellcome Co., Research
Triangle Park, N.C.) and sulfamethoxazole (range, 0.59 to
152 pLg/ml; Burroughs-Wellcome Co.) were incorporated
alone and in 1:19 combinations into HTM supplemented with
thymidine phosphorylase (0.2 IU/ml; Burroughs-Wellcome
Co.). Erythromycin (range, 0.03 to 32 jig/ml; Abbott Labo-
ratories, North Chicago, Ill.) and sulfisoxazole (range, 2.0 to
512 ,ug/ml; Sigma) also were added alone and in 1:64 com-
binations into HTM containing thymidine phosphorylase. A
1:64 ratio of these two agents was chosen for study on the
basis of the results of in vitro studies by Whitley and Pelton
(38) and in vivo drug level studies by Howard et al. (15).
Test inocula were prepared by suspending colonies from
an overnight growth of each isolate into Trypticase soy broth
to equal the turbidity of a no. 0.5 McFarland standard. The
standardized suspensions then were diluted 1:10 in Trypti-
case soy broth. Plates were inoculated with suspensions of
test strains (approximately 104 CFU per spot) by using a
Steers replicator (30). The inoculated HTM plates were
incubated at 35°C in CO2 for 18 to 24 h. The MIC was defined
as the lowest concentration of antimicrobial agent at which
growth was completely inhibited; a very fine, barely visible
haze or a single colony was not regarded as growth. When
trimethoprim and sulfonamides were tested, the endpoint
was taken as the lowest concentration of antimicrobial agent
demonstrating a sudden, sharp (80 to 90%) decrease in
growth (19). Escherichia coli ATCC 25922 and Streptococ-
cus faecalis ATCC 29212 were used as controls for each
experiment. The expected MICs for these two organisms
were observed for all the antimicrobial agents tested. MICs
were determined in duplicate on separate plates and on
separate days. The higher MIC of the duplicate values was
used for data analysis. None of the duplicate results differed
by more than one twofold dilution.
TABLE 1. Prevalence of ,B-lactamase production in 217
H. influenzae isolates recovered during 1979 through 1987
1979-1983 1984-1987
Classification No. of No. (%) of strains No. of No. (%) of strains
strains ,B-lactamase strains P-lactamase
tested positive tested positive
Total 104 19 (18) 113 20 (18)
Type b 15 11(73) 6 1 (17)
Type e 0 0 (0) 10 1(10)
Type f 2 0 (0) 12 0 (0)
Nontypeable 87 8 (9) 85 18 (21)
RESULTS
A total of 217 isolates of H. influenzae recovered between
1979 and 1987 from a total of 86 children attending the Frank
Porter Graham Child Development Center were examined
for their in vitro susceptibilities to a panel of 11 antimicrobial
agents. The average number of isolates tested was 2.5 per
child (range, 1 to 7). Among the 217 isolates, 10% were
serologically classified as type b, 5% as type e, 6% as type f,
and 79% as nontypeable.
The ability of H. influenzae isolates to produce P-lacta-
mase was determined by using the chromogenic cephalospo-
rin nitrocefin. Table 1 summarizes the prevalence of ,-lac-
tamase production and the distribution of that production by
isolate serotype. One hundred four of the strains tested were
recovered during 1979 through 1983. Nineteen (18%) of these
strains were positive for ,-lactamase production. Seventy-
three percent of the 15 type b strains recovered in this time
period produced 1-lactamase. None of the type e or f strains
and 9% of the 87 nontypeable strains were ,-lactamase
positive. One hundred thirteen strains were recovered dur-
ing the 1984 through 1987 time period, and 20 or, again, 18%
of those isolates were positive for ,-lactamase production.
Seventeen percent of the 6 type b strains, 10% of the type e
strains, 0% of the type f strains, and 21% of the 85 nontype-
able strains were positive for ,-lactamase production in the
later time period.
The in vitro susceptibility of H. influenzae to four beta-
lactam agents is shown in Table 2. The MICs of amoxicillin
for 50% (MlC50) and 90% (MIC90) of the P-lactamase-
positive strains tested were >16.0 jig/ml. Amoxicillin MICs
TABLE 2. MICs of four beta-lactam agents against 39
,-lactamase-positive strains and 178 3-lactamase-negative
strains of H. influenzae recovered during 1979 through 1987
Antimicrobial MIC (qLg/ml)a
agent ,-Lactamaseagent 50% 90% Range
Amoxicillin Positive >16.0 >16.0 4.0-16.0
Negative 1.0 1.0 0.125-1.0
Amoxicillin- Positive 1.0 2.0 0.5-4.0
clavulanateb Negative 0.5 1.0 0.125-1.0
Cefaclor Positive 8.0 16.0 2.0->16.0
Negative 4.0 16.0 1.0->16.0
Cefuroxime Positive 0.5 1.0 0.25-2.0
Negative 0.5 1.0 0.125-2.0
a 50% and 90%, MICs for 50 and 90% of isolates tested, respectively.
b This combination was tested at a constant ratio of 2 parts of amoxicillin to




TABLE 3. Susceptibility summary of seven antimicrobial
agents against 217 strains of H. influenzae recovered
during 1979 through 1987
Antimicrobial MIC (Lg/ml)a
agent 50% 90% Range
Chloramphenicol 0.5 1.0 0.06-4.0
Trimethoprim 0.5 4.0 0.06-8.0
Sulfamethoxazole >152.0 >152.0 19.0->152.0
Trimethoprim- 0.125/2.38 0.25/4.76 -0.03/0.59-1.0/
sulfamethoxazoleb 19.0
Erythromycin 4.0 8.0 0.25-16.0
Sulfisoxazole 128.0 128.0 8.0-256.0
Erythromycin- 2.0/128.0 2.0/128.0 0.25/16.0-4.0/
sulfisoxazolec 256.0
a 50%o and 90%o, MICs for 50 and 90o of isolates tested, respectively.
b This combination was tested at a constant ratio of 1 part of trimethoprim
to 19 parts of sulfamethoxazole.
c This combination was tested at a constant ratio of 1 part of erythromycin
to 64 parts of sulfisoxazole.
for all strains lacking 13-lactamase activity were .1.0 ,ug/ml.
All strains for which amoxicillin MICs were >1.0 ;ig/ml were
f-lactamase positive.
Clavulanic acid was effective in vitro in inhibiting f3-lacta-
mase activity, as indicated by the reduction of amoxicillin
MICs when a 2:1 combination of amoxicillin and clavulanic
acid was used to test ,-lactamase-positive strains.
Cefuroxime was found to be more active against the H.
influenzae isolates tested than was cefaclor, with MIC90s of
1.0 and 16.0 ,ug/ml, respectively. The cefaclor MIC was .1.0
,ug/ml for only one test isolate, while for more than 90% of
the test isolates, cefuroxime MICs were <1.0 ,ug/ml. As
indicated in Table 2, H. influenzae susceptibility to cepha-
losporins was not significantly influenced by P-lactamase
production.
The MICs of other antimicrobial agents for H. influenzae
are presented in Table 3. Chloramphenicol MICs were 4.0
,ug/ml for three isolates (1%), while chloramphenicol MICs
ranged from 0.06 to 1.0 ,ug/ml for the remaining strains. The
three strains with reduced susceptibility to chloramphenicol
were recovered from two of the children in the study, were
serologically nontypeable, and were P-lactamase positive.
Trimethoprim-sulfamethoxazole MICs ranged from c0.03/
0.59 to 1.00/19.0 jxg/ml, with a median MIC of 0.125/2.38
;ig/ml. Trimethoprim-sulfamethoxazole MICs for only 2
(<1%) of the 217 isolates studied were >0.5/9.5 jig/ml. The
two strains for which the MICs were increased were recov-
ered from different children, were serotype b, were 1-lacta-
mase positive, and were susceptible to chloramphenicol.
Trimethoprim MICs were c0.5 ,ug/ml for 65% of the H.
influenzae strains when they were tested against this antimi-
crobial agent alone. None of the isolates was inhibited by
sulfamethoxazole alone at concentrations of .9.5 ,ug/ml.
Antimicrobial synergy was displayed against 54% of the H.
influenzae strains tested; MICs of the two drugs in combi-
nation were greater than or equal to fourfold lower than the
MICs of trimethoprim and sulfamethoxazole when they were
tested separately against these isolates.
Erythromycin-sulfisoxazole MICs were .0.5/32 ,ug/ml for
only 5% of the isolates studied. High concentrations of
erythromycin and sulfisoxazole alone were required to in-
hibit the majority of strains tested. Erythromycin MICs were
s0.5 ,ug/ml for only 2% of the isolates studied, while
sulfisoxazole MICs were .32 ,ug/ml for 3% of the isolates
studied when they were tested against each of these two
drugs alone. Although the combination of erythromycin-
sulfisoxazole was more active than erythromycin alone, the
combination had activity essentially equal to that of sulfisox-
azole alone, with synergy demonstrated in only 0.5% of the
isolates tested.
Comparison of MIC50 and MIC90 data for 1979 through
1983 and 1984 through 1987 indicated no significant differ-
ences in susceptibilities to the antimicrobial agents during
the two time periods studied. In addition, the proportion of
isolates susceptible to concentrations of antimicrobial agents
usually achieved in middle ear fluid remained consistent over
the period of study (Table 4).
DISCUSSION
Recent reports have suggested that day-care center atten-
dance and trends in antibiotic use in children attending
day-care centers can influence the epidemiology of antimi-
crobial resistance in pediatric bacterial pathogens (13, 31).
We previously conducted an antibiotic resistance survey for
pneumococci in a day-care population and found periods of
time when the prevalence of pneumococci with reduced
susceptibilities to both penicillin G and trimethoprim-sul-
famethoxazole was relatively high (14). We undertook the
present investigation to survey the extent of antibiotic resis-
tance in strains of H. influenzae colonizing the upper respi-
ratory tracts of children attending the same day-care center.
Because otitis media was the most common illness requiring
TABLE 4. MICs and percent susceptibility of H. influenzae isolates recovered during 1979 through 1983 and
1984 through 1987 to commonly used oral antimicrobial agents
Concn 1979-1983 198441987
Antimicrobial agent achievable MIC (,ug/ml)D MIC (,ug/ml)in MEF % Susceptiblec % Susceptible
(Rg/ml)a 50% 90% 50% 90%
Amoxicillin 1.0 0.5 >16.0 82 0.5 16.0 82
Amoxicillin-clavulanate 1.0/0.5 0.5/0.25 1.0/0.5 88 0.5/0.25 1.0/0.5 97
Cefaclor 1.0 8.0 16.0 0 4.0 8.0 1
Cefuroxime 1.0 0.5 1.0 91 0.5 1.0 94
Trimethoprim-sulfamethoxazole 0.5/9.5 0.125/2.38 0.25/4.76 98 0.125/2.38 0.25/4.76 100
Erythromycin 0.5d 4.0 8.0 2 4.0 8.0 2
Erythromycin-sulfisoxazoled 0.5/32 2.0/128 2.0/128 2 2.0/128 2.0/128 7
a Concentration of antimicrobial agent usually achieved in middle ear fluid (MEF). See text for references.
b 50% and 90%o, MICs for 50 and 90%o of isolates tested, respectively.
c Percent susceptible to less than or equal to the concentration of antimicrobial agent usually achieved in middle ear fluid.
d Erythromycin concentration in middle ear fluid when administered as ethylsuccinate.
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antibiotic treatment in this group of children, susceptibility
results from this study were based on the concentrations of
antimicrobial agents achievable in middle ear fluid.
The overall rate of ,B-lactamase production for all the
isolates investigated in this study was 18%. P-Lactamase
production was documented in 57% of all the type b isolates
and 14% of the total non-type b isolates tested: On the basis
of a comparison of the ,B-lactamase positivity of total isolates
from the first 5 years of our study with that of the last 4
years, the prevalence of P-lactamase-producing H. influ-
enzae strains did not increase in our day-care population.
The serotype distribution of P-lactamase production did
appear to change; however, the number of organisms tested
was too small to determine the significance of this observa-
tion.
,B-Lactamase activity was inhibited, and reductions in the
amoxicillin MICs were demonstrated when 1-lactamase-
positive isolates were tested for their susceptibility to amox-
icillin in combination with the ,-lactamase inhibitor clavu-
lanic acid. However, for only 56% of these isolates tested
against this combination were amoxicillin MICs reduced to
the levels seen for P-lactamase negative strains or to levels
readily achieved in middle ear fluid (.1.0 ,ug/ml) (10, 15, 21,
26).
There was no apparent trend of increasing resistance to
cefaclor or cefuroxime among the isolates examined in the
present investigation. Of interest, however, was that cefur-
oxime MICs were .l1.0 jxg/ml for 201 (93%) of the 217 H.
influenzae strains tested, while cefaclor MICs were .1.0
,ug/ml for less than 1% of the isolates; .1.0 jig/ml is the
concentration of these cephalosporin agents usually attained
in middle ear fluid (7, 21, 23, 24, 26). Our findings regarding
cefaclor are compatible with those of other investigators. In
a 1978 study of clinical H. influenzae isolates, fewer than
10% of the strains were inhibited by a concentration of 0.78
,g of cefaclor per ml (29). In a more recent national survey
of 2,811 clinical isolates, only 5% were inhibited by cefaclor
at a concentration of .1.0 jig/ml (6). In contrast to cefaclor,
the cefuroxime MIC90 for 100 clinical isolates in a 1983 study
was 1.0 j,g/ml (8).
H. influenzae strains for which chloramphenicol MICs
were >2.0 ,ug/ml were uncommon (1%) in the strains from
the day-care population that we studied, as they have been in
recent national surveys (5, 6). Since 1972, chloramphenicol
resistance has been reported in both type b and non-type b
H. influenzae clinical isolates. A large proportion of these
clinical strains also have been resistant to ampicillin, tetra-
cycline, and trimethoprim-sulfamethoxazole (3, 25). All
three of our strains for which chloramphenicol MICs were
increased were non-type b and I-lactamase positive, but
they were trimethoprim-sulfamethoxazole susceptible. Tet-
racycline was not tested against our study isolates.
The antimicrobial combination trimethoprim-sulfamethox-
azole was highly active in vitro against our H. influenzae
study strains at concentrations achievable in middle ear
fluid, .0.5/9.5 jig/ml (20, 21). Antibiotic synergy was dem-
onstrated against 54% of the study isolates tested against this
combination. In studies by other investigators, -99% of
both clinical isolates and survey isolates from healthy chil-
dren were susceptible to .0.5/9.5 ug of trimethoprim-sul-
famethoxazole per ml (4, 6, 29). The opposite was true in our
previous experience with pneumococci (14); the use of
trimethoprim-sulfamethoxazole resulted in the rapid selec-
tion of strains with reduced susceptibilities to this drug
combination. Before the introduction of trimethoprim-sul-
famethoxazole in 1981, pneumococcal resistance to this drug
was only 5% in the day-care study population. Resistance
rose to 39%, however, during the 5 years following the
introduction of this antimicrobial agent. Of interest is the
fact that the H. influenzae isolates we tested in the present
study had experienced the same antibiotic pressures as the
previously tested pneumococcal isolates, yet there was no
increase in the prevalence of resistance to trimethoprim-
sulfamethoxazole in the H. influenzae isolates examined in
this study.
High concentrations of both erythromycin and sulfisox-
azole alone and in combination were required to inhibit the
majority of H. influenzae strains studied in the present
investigation. On the basis of the current literature, probably
no more than 0.5 ,ug of erythromycin per ml is achievable in
the middle ear when it is given in the form of erythromycin
ethylsuccinate (1, 10, 26, 33); 98% of the isolates we tested
were not susceptible to this concentration of erythromycin in
vitro. In a recent national survey, comparable results were
observed, in which erythromycin MICs were s0.5 ,ug/ml for
only 1% of the strains tested (6).
Erythromycin ethylsuccinate-sulfisoxazole is a commonly
prescribed combination therapy for otitis media (1, 10, 26,
33). However, in this investigation we found a very high
prevalence (95%) of H. influenzae strains that were not
susceptible to this combination in vitro when s0.5/32.0 ,ug of
erythromycin-sulfisoxazole per ml was used as the criterion
for susceptibility. In another study that tested the same ratio
of these two drugs, only 37% of the H. influenzae isolates
were inhibited by O0.5/32 ,ug of the combination per ml (32).
Also, in our investigation we found little evidence that the
combination of erythromycin and sulfisoxazole (1:64) is
synergistic against those isolates tested.
In this investigation, we studied in a longitudinal fashion
the in vitro antimicrobial susceptibility of H. influenzae
isolates recovered from nasopharyngeal secretions of chil-
dren known to have high rates of exposure to antibiotics
secondary to increased rates of otitis media. The survey was
undertaken to determine the prevalence of resistance to
antimicrobial agents commonly used for the treatment of
middle ear infections. In particular, we were interested in
trends in resistance to trimethoprim-sulfamethoxazole be-
cause increases in resistance to this antimicrobial agent were
previously documented in pneumococci carried by children
in this same population. In summary, many of the H.
influenzae isolates tested were not susceptible to the antimi-
crobial concentrations achievable in middle ear fluid; how-
ever, there was no observable trend toward resistance to
trimethoprim-sulfamethoxazole or to any of the other oral
antimicrobial agents studied in this investigation.
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